JP5087389B2 - 慢性心不全を治療するためのペルヘキシリン - Google Patents
慢性心不全を治療するためのペルヘキシリン Download PDFInfo
- Publication number
- JP5087389B2 JP5087389B2 JP2007502376A JP2007502376A JP5087389B2 JP 5087389 B2 JP5087389 B2 JP 5087389B2 JP 2007502376 A JP2007502376 A JP 2007502376A JP 2007502376 A JP2007502376 A JP 2007502376A JP 5087389 B2 JP5087389 B2 JP 5087389B2
- Authority
- JP
- Japan
- Prior art keywords
- heart failure
- perhexiline
- chronic heart
- treatment
- ischemia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
- A61K31/37—Coumarins, e.g. psoralen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4458—Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
- Electrotherapy Devices (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
(心肺運動負荷試験)
ウェーバープロトコル(Weber protocol)を用いて、トレッドミル上で呼気ガス交換の評価を伴う漸増運動負荷試験を実施した。各試験前に較正されたPulmolab EX670質量分析計を使用して、試験中にひと呼吸ごとの呼気ガスを測定した。生データを30秒間隔で平均し、最大運動時の酸素消費量を求めた(VO2max;ml/kg/分)。開始から終了までの間、電子心電図および血圧を測定した。運動は、疲労または息切れによる被験者の要求があった際に終了した。
MLHFQの標準的な21項目の質問書を採用し、ペルヘキシリンが患者のクオリティオブライフ(QOL))に影響を与えるか否かを決定した。この質問書は心不全(17)における症候学の非常に有効な尺度であり、日常生活を営む能力を評価する質問および心不全による症状の重症度を評価する質問が含まれる。各質問は5段階で採点した。点数の合計を計算した。高い点数は低いQOLを示す。全ての患者が援助なしに質問書の記載を終了した。
Vingmed System V心エコー検査機および2.5MHzの変換器を使用して、左側臥位で患者に対してエコー検査を実施した。画像はデジタル形式で保存した。LVEF、僧幅弁ドプラ法、安静時組織ドプラ法用の標準的な心エコー検査用画面を使用し、安静時のスキャンを得た。組織ドプラ法による心エコー検査により、局所壁運動の目的分析が可能となり、ドブタミン負荷(18)と共に使用した場合、従来のグレースケール心エコー検査よりも優れている。
左心室の組織ドプラ法による評価を安静時に行い、別の箇所(20)に詳細に記述した15箇所の左室部位の局所心筋PSVを測定するために、Echopacソフトウェアを使用してオフライン解析した。PSV(21)を取得するための最大再現性を得るために、3つの主要な冠動脈から供給された全範囲を含めるように左室部位を選択した(図4参照)。
安静時心エコー検査に続いて、注射器によってドブタミン注入を開始し、3分間隔で注入量を5mcg/kg/分から10、20、30、40mcg/kg/分まで増量した。上述した15の画像のデジタルループを各段階の90秒の時点で記録した。血行動態反応が最大ではない場合には、アトロピンを最大1mgまで投与した。心電図と血圧を各段階で測定した。試験は、目標心拍数の85%以上の達成、虚血の所見、あるいはドブタミンによる重篤な副作用があった場合に終了した。安静時の画像と同様に、全ての段階からのデータをオフライン分析した。
(31P磁気共鳴分光法)
CHFの患者は、運動時に異常な速さで骨格筋ホスホクレアチン(筋収縮に大きく関係する高エネルギーリン酸塩(phosphate)代謝物質)が欠乏し、回復も遅い(22)。31P磁気共鳴分光法により、骨格筋細胞内高エネルギーリン酸塩化合物およびpHの変化を非侵襲的に測定することが可能となる。運動の最後には、グリコーゲン分解が停止し、ホスホクレアチン再合成が純粋に酸化によって行われるため、ホスホクレアチンの回復を分析することにより、骨格筋ミトコンドリア機能についての情報が得られる。筋肉エネルギー論に対する上昇するブドウ糖代謝の効果を測定するために、腓筋の磁気共鳴分光法を局所運動前、局所運動時、局所運動後に実施した。潜在的な末梢血管の疾患は、心不全と無関係に骨格筋エネルギー論の異常に繋がるため、非虚血性心不全群の患者のみに対して磁気共鳴分光法を行った。
ベースライン試験に続いて、ペルヘキシリン(n=28)あるいはプラセボ(n=28)を1日当たり2回、100mgを投与する患者を二重盲検法で無作為に抽出した。毒性を防ぐため、投与後の滴定で血清ペルヘキシリンレベルを測定するため、薬剤の使用を開始してから1、4、8週間後に血液を採取した。非盲検の医者が、標準的なプロトコルにより用量調整を助言した。治験責任医師の盲視を確実に維持するため、非盲検の監視者が同一の用量調整を無作為に配分したプラセボ投与患者にも行なった。8週間の治療の後、患者を上述の方法と同様に再評価した。
試験の主要評価項目はVO2maxとし、以下の項目を副次的評価項目として予め定めた。MLHFQスコア、LVEF、E:EA比、負荷心エコー検査における安静時、低用量時、高用量時の平均PSV、およびPCr t1/2。虚血群と非虚血群の治療の無作為抽出は別々に行なったが、該抽出は、各群での主要評価項目のpre−hoc分析を考慮して類似のプロトコルで行なった。試験は95%の検知力を有しており、0.05の有意レベルでペルヘキシリン群対プラセボ群のVO2maxにおける2ml/kg/分の増加を検出した。データはWindows(登録商標)のSPSS11.5で分析し、平均±標準誤差で表した。治療後、ペルヘキシリン群対プラセボ群で見られた差異の有意性試験を行なうために、ベースライン値を共分散として使用するANCOVAを実施した。p値が<0.05の場合、統計的有意を示すとみなした。
全ての患者が8週間の治療を終了した。試験期間中、いずれの群にも死亡した者はいなかった。ペルヘキシリン群の副作用は、治療第1週目に生じた短時間の悪心とめまいのみであった(n=3)。両群ともにベースラインの特徴および治療によく適合していた(表1)。治療後、ペルヘキシリン群内においてNYHAクラスの有意な減少が見られた(p=0.02)。
これらの実験の結果として、ペルヘキシリンの使用が、最高到達運動容量、安静時および負荷時の心筋機能、患者から報告された症状および骨格筋エネルギー論に有意な改善をもたらしたことが判明した。特筆すべきことに、これらの改善は、統計学的に大いに重要であると共に、既に最適な治療を受けた患者における臨床的に有意な改善も表している。我々が得た結果は、CHFの初期誘発作用に関係なく、深刻な副作用を生じさせずに、ペルヘキシリンがこれらのパラメータを一貫して改善させることを示唆している。
Claims (5)
- ペルヘキシリンまたはその薬学的に許容される塩を、有効成分として含有する、虚血誘発を原因とする慢性心不全の治療用医薬。
- ペルヘキシリンの薬学的に許容される塩を、有効成分として含有する、虚血誘発を原因とする慢性心不全の治療用医薬。
- ペルヘキシリンのマレイン酸塩を、有効成分として含有する、虚血誘発を原因とする慢性心不全の治療用医薬。
- 慢性心不全またはその兆候の治療に有効な1以上の他の化合物と、請求項1ないし3のいずれか一項に記載の医薬と、を含む、虚血誘発を原因とする慢性心不全の治療用医薬組成物。
- ペルヘキシリンまたはその薬学的に許容される塩を有効成分として含有し、前記ペルヘキシリンの血清レベルが0.15〜0.60mg/lであることを監視および維持しながら投与される、虚血誘発を原因とする慢性心不全の治療用医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0405381.5 | 2004-03-10 | ||
GBGB0405381.5A GB0405381D0 (en) | 2004-03-10 | 2004-03-10 | A method and means for treating heart failure |
PCT/GB2004/003835 WO2005087233A1 (en) | 2004-03-10 | 2004-09-07 | Perhexilin for treating chronic heart failure |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007528378A JP2007528378A (ja) | 2007-10-11 |
JP5087389B2 true JP5087389B2 (ja) | 2012-12-05 |
Family
ID=32117402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007502376A Expired - Fee Related JP5087389B2 (ja) | 2004-03-10 | 2004-09-07 | 慢性心不全を治療するためのペルヘキシリン |
Country Status (13)
Country | Link |
---|---|
US (4) | US20070275997A1 (ja) |
EP (1) | EP1732551B1 (ja) |
JP (1) | JP5087389B2 (ja) |
CN (1) | CN1950084A (ja) |
AT (1) | ATE487480T1 (ja) |
DE (1) | DE602004030048D1 (ja) |
DK (1) | DK1732551T3 (ja) |
ES (1) | ES2358514T3 (ja) |
GB (1) | GB0405381D0 (ja) |
MX (1) | MXPA06010397A (ja) |
PL (1) | PL1732551T3 (ja) |
PT (1) | PT1732551E (ja) |
WO (1) | WO2005087233A1 (ja) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
GB0723100D0 (en) * | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
GB0908193D0 (en) * | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
CA2816448A1 (en) * | 2009-05-20 | 2010-11-25 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
US9393221B2 (en) | 2011-07-20 | 2016-07-19 | The General Hospital Corporation | Methods and compounds for reducing intracellular lipid storage |
US20140065241A1 (en) * | 2012-09-05 | 2014-03-06 | Adelaide Research & Innovation Pty Ltd | Uses of (-)-perhexiline |
CN102988347A (zh) * | 2012-11-19 | 2013-03-27 | 何晓涛 | Aphanamixoid A在制备治疗或预防慢性心衰的药物中的应用 |
GB201308736D0 (en) * | 2013-05-15 | 2013-06-26 | Univ Aberdeen | Compounds and their therapeutic use |
JP2015147787A (ja) * | 2015-04-01 | 2015-08-20 | ハート メタボリクス リミテッド | 正常駆出率心不全の治療 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPN380695A0 (en) * | 1995-06-23 | 1995-07-20 | Queen Elizabeth Hospital, The | Methods related to the treatment of and isolation of compounds for treatment of ischaemic conditions |
US20030162824A1 (en) * | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
CL2004000366A1 (es) * | 2003-02-26 | 2005-01-07 | Pharmacia Corp Sa Organizada B | USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA. |
GB0405381D0 (en) | 2004-03-10 | 2004-04-21 | Univ Wales Medicine | A method and means for treating heart failure |
AU2005230811A1 (en) | 2004-04-06 | 2005-10-20 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
GB0723100D0 (en) | 2007-11-23 | 2008-01-02 | Heart Metabolics Ltd | Treatment of HFnEF |
GB0908193D0 (en) | 2009-05-13 | 2009-06-24 | Albright Patents | Treatment of disease state |
CA2816448A1 (en) | 2009-05-20 | 2010-11-25 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
-
2004
- 2004-03-10 GB GBGB0405381.5A patent/GB0405381D0/en not_active Ceased
- 2004-09-07 JP JP2007502376A patent/JP5087389B2/ja not_active Expired - Fee Related
- 2004-09-07 WO PCT/GB2004/003835 patent/WO2005087233A1/en active Application Filing
- 2004-09-07 CN CNA2004800429346A patent/CN1950084A/zh active Pending
- 2004-09-07 EP EP04768382A patent/EP1732551B1/en not_active Not-in-force
- 2004-09-07 US US10/592,250 patent/US20070275997A1/en not_active Abandoned
- 2004-09-07 ES ES04768382T patent/ES2358514T3/es active Active
- 2004-09-07 MX MXPA06010397A patent/MXPA06010397A/es active IP Right Grant
- 2004-09-07 AT AT04768382T patent/ATE487480T1/de active
- 2004-09-07 DE DE602004030048T patent/DE602004030048D1/de active Active
- 2004-09-07 PT PT04768382T patent/PT1732551E/pt unknown
- 2004-09-07 PL PL04768382T patent/PL1732551T3/pl unknown
- 2004-09-07 DK DK04768382.6T patent/DK1732551T3/da active
-
2011
- 2011-09-23 US US13/244,103 patent/US8470806B2/en not_active Expired - Fee Related
-
2013
- 2013-03-15 US US13/841,635 patent/US20130331321A1/en not_active Abandoned
- 2013-03-15 US US13/841,465 patent/US8697677B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US8697677B2 (en) | 2014-04-15 |
US20120101128A1 (en) | 2012-04-26 |
US8470806B2 (en) | 2013-06-25 |
ATE487480T1 (de) | 2010-11-15 |
PL1732551T3 (pl) | 2011-05-31 |
CN1950084A (zh) | 2007-04-18 |
EP1732551A1 (en) | 2006-12-20 |
WO2005087233A1 (en) | 2005-09-22 |
US20130224118A1 (en) | 2013-08-29 |
US20130331321A1 (en) | 2013-12-12 |
PT1732551E (pt) | 2011-02-15 |
DE602004030048D1 (de) | 2010-12-23 |
EP1732551B1 (en) | 2010-11-10 |
JP2007528378A (ja) | 2007-10-11 |
GB0405381D0 (en) | 2004-04-21 |
DK1732551T3 (da) | 2011-02-28 |
MXPA06010397A (es) | 2007-04-23 |
US20070275997A1 (en) | 2007-11-29 |
ES2358514T3 (es) | 2011-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8470806B2 (en) | Perhexiline for treating chronic heart failure | |
US20110166220A1 (en) | Dronedarone for the prevention of permanent atrial fibrillation | |
US20120122925A1 (en) | Perhexiline for use in the treatment of hypertrophic cardiomyopathy (hcm) | |
PT1467728E (pt) | Composições farmacêuticas compreendendo valsartan e inibidores da nep | |
KR20110117655A (ko) | 발기 부전의 치료를 위한 sgc 자극제 또는 sgc 활성화제와 pde5 억제제의 조합물 | |
JP2011529958A (ja) | 脳卒中または一過性脳虚血発作を予防するための薬物を調製するためのドロネダロンの使用 | |
JP6499634B2 (ja) | 過活動膀胱の治療のためのソリフェナシンと唾液分泌刺激剤の組合せ | |
US8602215B2 (en) | Methods for reducing the risk of an adverse dronedarone/beta-blockers interaction in a patient suffering from atrial fibrillation | |
SK19332001A3 (sk) | Použitie antagonistov kortizolu v liečení srdcového zlyhania | |
CN103315968B (zh) | 一种注射用粉针剂及其制备方法 | |
Morisco et al. | Lisinopril in the treatment of congestive heart failure in elderly patients: comparison versus captopril | |
JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
White et al. | Chronotherapeutic delivery of verapamil in obese versus non-obese patients with essential hypertension | |
JP7082258B2 (ja) | うっ血性心不全に罹っている対象を治療するためのリボースの使用 | |
JP2005531492A (ja) | 高リスク患者のii型糖尿病を低減させる方法 | |
MX2013013124A (es) | Combinaciones de trospio y estimulantes salivales para el tratamiento de la vejiga hiperactiva. | |
CA2245095A1 (en) | Method for treating heart failure | |
Molajo et al. | The effects and dose‐response relationship of xamoterol in patients with ischaemic heart disease. | |
Ivanović et al. | Fixed combination of bisoprolol and a low-dose hydrochlorothiazide in arterial hypertension | |
WO2023200738A1 (en) | Combination treatment of dilated cardiomyopathy comprising a tyrosine kinase inhibitor and a statin | |
Taylor et al. | Efficacy of ibopamine in the treatment of heart failure | |
WO2006061341A1 (en) | Use of propionyl l-carnitine for the preparation of a high-dose medicament for the treatment of peripheral arterial disease | |
WO2010057066A1 (en) | Pharmacokinetically-based dosing regimens of a thrombin receptor antagonist | |
AU2010202742A1 (en) | Methods for reducing the risk of an adverse dronedarone / beta-blockers interaction in a patient suffering from atrial fibrillation | |
WO2007040128A1 (ja) | 心不全治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070905 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110411 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110418 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110509 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110516 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110603 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110610 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111202 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111209 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111229 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120210 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120622 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120815 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120910 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150914 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |